Metal protein attenuating compounds for the treatment of Alzheimer's dementia

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 2, 2014, Pages

  Sampson, Elizabeth L ^a   Jenagaratnam, Lydia ^b   Mcshane, Rupert ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLIOQUINOL; NOOTROPIC AGENT; PBT2; PLACEBO; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; CHELATING AGENT; DRUG DERIVATIVE; PBT2 COMPOUND;

ALZHEIMER DISEASE; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; COLOR VISION DEFECT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FUNCTIONAL ASSESSMENT; HUMAN; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING; VISUAL IMPAIRMENT; AGED; META ANALYSIS; METABOLISM;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CHELATING AGENTS; CLIOQUINOL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907646346     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005380.pub5     Document Type: Review

References (27)

1. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al.Safety, efficacy and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa double-blind randomised placebo-controlled trial. Lancet Neurology 2008;7:779-86.
2. Ritchie CW, Bush AI, Mackinnon A, et al.Metal-protein attenuation with iodo-chlorhroxyquin(clioquinol) targeting Aß amyloid deposition and toxicity in Alzheimer disease:a pilot phase 2 clinical trial. Archives of Neurology 2003;60:1685-91.
3. Finefrock AE, Bush AI, Doraiswamy PM. Current status of metals as therapeutic targets in Alzheimer's disease. Journal of the American Geriatrics Society 2003;51(8):1143-8.
4. Mastwyk M, Macfarlane S, LoGiudice D, Sullivan KA. Why participate in an Alzheimer's disease clinical trial? Is it of benefit to carers and patients?. International Psychogeriatrics IPA 2003;15(2):149-56.
5. Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, et al.Treatment of Alzheimer's disease with clioquinol. Dementia and Geriatric Cognitive Disorders 2001;12(6):408-14.
6. Adlard PA, Cherny RA, Finkelstein DI, et al.Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxyquinolone analogs is associated with decreased interstitial Aß. Neuron 2008;59:43-55.
7. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Library. John Wiley & Sons, Ltd, 2011, issue 1:Chapter 8.
8. Attwood CS, Martins RN, Smith MA, Perry G. Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. Peptides 2002;23:1343-50.
9. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health 1998;88:1337-42.
10. Bush AI, Pettingell WH, Maulthaup G, et al.Rapid induction of Alzheimer Aß amyloid formation by zinc. Science 1994;265:1464-7.
11. Bush AI. The metallobiology of Alzheimer's disease. Trends Neuroscience 2003;26:207-14.
12. Cherny RA, Atwood CS, Xilianas ME, et al.Treatment with copper-zinc chelator markedly and rapidly inhibits ß-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-76.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3th revised. Washington, DC: American Psychiatric Association, 1987.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994.
15. Faux NG, Ritchie CW, Gunn A, et al.PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. Journal of Alzheimers Disease 2010;20(2):509-16.
16. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatry Research 1975;12:189-98.
17. Harrison J, Minassian SL, Jenkins L, et al.A neuropsychological test battery for use in Alzheimer disease clinical trials. Archives of Neurology 2007;64:1323-9.
18. Knopman DS, Knapp MJ, Gracon SI, Davis, CS. The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315.
19. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, et al.Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. (Erratum). Lancet Neurology 2009;8(11):981.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1994;34:939-44.
21. Prana Completes Review of Development Programme. http://www.pranabio.com/downloads/Media%20Releases/2005%2016%20June%20Prana%20Completes%20Review%20of%20Development%20Plan.pdf 16th June 2005.
22. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry 1984;11:1356-64.
23. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines. Geneva: World Health Organization, Division of Mental Health, 1992.
24. Wirths O, Multhaup G, Bayer TA. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. Neurochemistry 2004;91:513-20.
25. Yassin MS, Ekblom J, Xilinas M, Gottfries CG, Oreland L. Changes in uptake of vitamin B12 and trace metals in brains of mice treated with clioquinol. Journal of Neurological Science 2000;173:40-4.
26. Jenagaratnam L, McShane R. Clioquinol for the treatment of Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1.
27. Sampson E, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. Cochrane Database of Systematic Reviews 2008, Issue 1.